Revolution Medicines, Inc. RVMD
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Each USD of equity lost 58 cents this year.
The 8-year record
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 |
| Operating income $B | −1.2 | −0.7 | −0.5 | −0.3 | −0.2 | −0.1 | −0.1 | −0.0 |
| EBITDA $B | −1.2 | −0.7 | −0.5 | −0.3 | −0.2 | −0.1 | −0.1 | −0.0 |
| Income tax $B | 0.0 | −0.0 | −0.0 | −0.0 | 0.0 | −0.0 | −0.0 | ◌ |
| Net income $B | −1.1 | −0.6 | −0.4 | −0.2 | −0.2 | −0.1 | −0.0 | −0.0 |
| Free cash flow $B | −0.9 | −0.6 | −0.4 | −0.2 | −0.2 | −0.1 | −0.1 | −0.0 |
| EPS, diluted $ | −5.95 | −3.58 | −3.86 | −3.08 | −2.57 | −2.01 | −22.33 | −21.24 |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % | — | — | — | — | — | −0 | — | — |
| ROE % | −58.1 | −29.3 | −34.8 | −38.6 | −34.7 | — | — | — |
| Shares out B | 0.20 | 0.19 | 0.16 | 0.09 | 0.07 | 0.07 | 0.00 | ◌ |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Company facts, as filed
Reconciled in 8 of the 8 fiscal years we could check. 24 checks were skipped: the balance sheet is not tagged before 2019. 11 checks were skipped: EPS is not tagged before 2018.